Long-acting amylin analogue. Work out exactly what to draw for your own mix, see the doses used in research, and follow a week-by-week plan. Evidence tier: clinical.
These are long-acting and reach steady state over weeks, so a single day’s timing has little effect. Consistency matters more than the hour.
| When | Dose | How Often | How Many mL | Draw To | Number Of Doses | Peptide Used |
|---|---|---|---|---|---|---|
| Weeks 1–4 | 0.3 mg | once weekly | 0.06 mL | 6 u | 4 | 1.2 mg |
| Weeks 5–8 | 0.6 mg | once weekly | 0.12 mL | 12 u | 4 | 2.4 mg |
| Weeks 9–12 | 1.2 mg | once weekly | 0.24 mL | 24 u | 4 | 4.8 mg |
| Week 13 onward per 4 weeks from here on |
2.4 mg | once weekly | 0.48 mL | 48 u | 4 | 9.6 mg |
| Level | Dose | How Often | How Many mL | Draw To | Doses In Vial |
|---|---|---|---|---|---|
| Initiation | 0.3 mg | once weekly | 0.06 mL | 6 u | 33 doses |
| Step | 0.6 mg | once weekly | 0.12 mL | 12 u | 16 doses |
| Step | 1.2 mg | once weekly | 0.24 mL | 24 u | 8 doses |
| Trial max | 2.4 mg | once weekly | 0.48 mL | 48 u | 4 doses |
An amylin analogue studied alone and in fixed combination with semaglutide (CagriSema). Escalation mirrors the GLP-1 pattern.
Buy CagrilintidePaid affiliate links.
Adding 2 mL of bacteriostatic water to a 10 mg vial gives 5 mg/mL. That is the mix every number on this page is worked out from — change the water figure in the calculator and all the draw amounts update.
Published and reported figures for Cagrilintide run from 0.3 mg to 2.4 mg, typically once weekly.3 mg to 2.4 mg, typically once weekly.3 mg to 2.4 mg, typically once weekly. This site lists each figure with the source it came from rather than giving a single recommended number.
At 5 mg/mL, a 0.3 mg dose is 6 units on a 1 mL U-100 insulin syringe. One vial at that mix gives about 33 doses.
Cagrilintide is graded clinical. Human trial or approved-label dosing has been published for this compound. We grade every compound on this site so you can weigh the numbers accordingly — the full method is on our editorial policy page.
Yes — Phase 2 escalation. The week-by-week table on this page converts each step into the exact amount to draw for your mix.
Compounds in the same class, or browse the full catalogue.
A small-molecule NNMT inhibitor rather than a true peptide. Research data show reduced adiposity in diet-induced obesity models. D…
Every compound compared in one table: dose range, how often, half-life and evidence tier.
Need this on one page to print, screenshot or send?
Make a dose card →